IP Library Granted Patent US 11,906,520
Granted Patent B2
US 11,906,520 · App. 16/692,574 · Granted Feb 20, 2024

Composition and methods for detecting cancer

Inventors: Valérie Molinier Frenkel (Saint Maur des Fossés, FR); Flavia Castellano (Antony, FR)
Assignees: Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Rech. Med.; Universite Paris Est Creteil Val De Marne
G01N33/57484C07K16/247C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,906,520
App. No.
16/692,574
Granted
Feb 20, 2024
Kind
B2
Abstract

The invention relates to antibodies, which bind a peptide having a sequence selected from SEQ ID NO: 2, or a fragment or derivative of such an antibody having essentially the same antigen specificity. In particular, the antibodies suited to be used to detect, manage or monitor cancer in a subject, particularly cancer with interleukin-4 induced gene 1 (IL4I1) expressing cells. The invention also relates to kits or devices containing said antibodies, suitable for immunologic detection or reaction from any biological sample.

Claims (20)

1. An isolated monoclonal antibody comprising:

a heavy chain comprising variable domain CDR sequences comprising:

(a) a H-CDR1 comprising the sequence of SEQ ID NO: 8,

(b) a H-CDR2 comprising the sequence of SEQ ID NO: 9 or SEQ ID NO: 18, and

(c) a H-CDR3 comprising the sequence of SEQ ID NO: 10 or SEQ ID NO: 19; and

a light chain comprising variable domain CDR sequences comprising:

(a) a L-CDR1 comprising the sequence of SEQ ID NO: 5,

(b) a L-CDR2 comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 14, and

(c) a L-CDR3 comprising the sequence of SEQ ID NO: 7 or SEQ ID NO: 15.

2. The isolated monoclonal antibody according to claim 1 , wherein:

the variable domain CDR sequences of the light chain consist of SEQ ID NO: 5 for L-CDR1, SEQ ID NO: 6 for L-CDR2 and SEQ ID NO: 7 for L-CDR3; and

the variable domain CDR sequences of the heavy chain consist of SEQ ID NO: 8 for H-CDR1, SEQ ID NO: 9 for H-CDR2 and SEQ ID NO: 10 for H-CDR3.

3. The isolated monoclonal antibody according to claim 1 , wherein:

the variable domain CDR sequences of the light chain consist of SEQ ID NO: 5 for L-CDR1, SEQ ID NO: 14 for L-CDR2 and SEQ ID NO: 15 for L-CDR3; and

the variable domain CDR sequences of the heavy chain consist of SEQ ID NO: 8 for H-CDR1, SEQ ID NO: 18 for H-CDR2 and SEQ ID NO: 19 for H-CDR3.

4. A device comprising the isolated monoclonal antibody according to claim 1 immobilized on a support.

5. The device of claim 4 , wherein the support is a membrane, a slide, a microarray, a chip, a microbead or a quartz prism.

6. A kit comprising the isolated monoclonal antibody according to claim 1 .

7. The kit according to claim 6 further comprising at least one reagent for performing or detecting an immune reaction.

8. An isolated monoclonal antibody produced from the hybridoma cell available under CNCM deposit number I-5355.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2020
From: MOLINIER FRENKEL, VALERIE; CASTELLANO, FLAVIA
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Reel/Frame 051748/0018 →
Priority Claims (1)
EP 18306563 · Nov 23, 2018 · regional
Continuity (1)
Related Publication 20200166512A1 · May 28, 2020